Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Stok Raporu

Piyasa değeri: US$458.7m

Rigel Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Rigel Pharmaceuticals CEO'su Raul Rodriguez, May2010 tarihinde atandı, in görev süresi 14.5 yıldır. in toplam yıllık tazminatı $ 3.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.2% maaş ve 78.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.74% ine doğrudan sahiptir ve bu hisseler $ 3.42M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 6.3 yıldır.

Anahtar bilgiler

Raul Rodriguez

İcra Kurulu Başkanı

US$3.4m

Toplam tazminat

CEO maaş yüzdesi21.2%
CEO görev süresi14.5yrs
CEO sahipliği0.7%
Yönetim ortalama görev süresi3.5yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30
There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Oct 10

Rigel Pharma adds ~7% to reach over two month high

Aug 18

Rigel rises 17% on strong Q2 result

Aug 03

Rigel Pharmaceuticals: A Status Check

May 31

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Rigel Pharmaceuticals: Why The Stock Is On A Run

Mar 21

CEO Tazminat Analizi

Raul Rodriguez'un ücretlendirmesi Rigel Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$4m

Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$3mUS$728k

-US$25m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$700k

-US$59m

Sep 30 2022n/an/a

-US$83m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$3mUS$662k

-US$18m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$662k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$3mUS$649k

-US$67m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$64m

Dec 31 2018US$4mUS$637k

-US$70m

Sep 30 2018n/an/a

-US$100m

Jun 30 2018n/an/a

-US$93m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$2mUS$618k

-US$78m

Tazminat ve Piyasa: Raul 'nin toplam tazminatı ($USD 3.44M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.14M ).

Tazminat ve Kazançlar: Raul 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Raul Rodriguez (63 yo)

14.5yrs

Görev süresi

US$3,440,790

Tazminat

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Raul Rodriguez
President14.5yrsUS$3.44m0.74%
$ 3.4m
Dean Schorno
Executive VP & CFO6.5yrsUS$1.21m0.069%
$ 316.7k
Raymond Furey
Executive VP1.9yrsUS$683.00k0.0028%
$ 13.0k
David Santos
Executive VP & Chief Commercial Officer4.3yrsUS$1.34m0.031%
$ 143.4k
Julie Patel
Senior VP of Human Resources2.8yrsVeri yokVeri yok
Esteban Masuda
Executive Vice President of Research8.2yrsUS$796.09kVeri yok
Joseph Lasaga
Executive VP & Chief Business Officerless than a yearVeri yokVeri yok
Lisa Rojkjaer
Executive VP & Chief Medical Officerless than a yearVeri yokVeri yok
Tarek Sallam
Vice President of Marketingno dataVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: RIGL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Raul Rodriguez
President10yrsUS$3.44m0.74%
$ 3.4m
Walter Moos
Independent Director27.7yrsUS$138.58k0.044%
$ 201.1k
Jane Wasman
Independent Director5.7yrsUS$145.58k0.043%
$ 195.3k
Gregory Lapointe
Independent Chairman of the Board7yrsUS$190.58k0.043%
$ 195.3k
Kamil Jackson
Independent Director2.9yrsUS$140.58k0.025%
$ 113.9k
Alison Hannah
Independent Director3.5yrsUS$212.98k0.032%
$ 146.5k

6.3yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RIGL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).